{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:41:49Z","timestamp":1769200909507,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1471-2350-10-124","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T19:14:13Z","timestamp":1259781253000},"source":"Crossref","is-referenced-by-count":65,"title":["Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population"],"prefix":"10.1186","volume":"10","author":[{"given":"William","family":"Kudzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander NO","family":"Dodoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy J","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"issue":"2","key":"538_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/00008571-200203000-00006","volume":"12","author":"JK Lamba","year":"2002","unstructured":"Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG: Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002, 12 (2): 121-132. 10.1097\/00008571-200203000-00006.","journal-title":"Pharmacogenetics"},{"issue":"1","key":"538_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF03256440","volume":"10","author":"E Garcia-Martin","year":"2006","unstructured":"Garcia-Martin E, Martinez C, Ladero JM, Agundez JA: Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther. 2006, 10 (1): 29-40.","journal-title":"Mol Diagn Ther"},{"issue":"4","key":"538_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","volume":"52","author":"JA Goldstein","year":"2001","unstructured":"Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001, 52 (4): 349-355. 10.1046\/j.0306-5251.2001.01499.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"538_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0300-483X(03)00247-6","volume":"192","author":"M Pirmohamed","year":"2003","unstructured":"Pirmohamed M, Park BK: Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology. 2003, 192 (1): 23-32. 10.1016\/S0300-483X(03)00247-6.","journal-title":"Toxicology"},{"issue":"3","key":"538_CR5","first-page":"242","volume":"29","author":"S Gerbal-Chaloin","year":"2001","unstructured":"Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrere N, Maurel P: Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001, 29 (3): 242-251.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"538_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","volume":"11","author":"D Dai","year":"2001","unstructured":"Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001, 11 (7): 597-607. 10.1097\/00008571-200110000-00006.","journal-title":"Pharmacogenetics"},{"issue":"12","key":"538_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/00008571-200312000-00002","volume":"13","author":"U Yasar","year":"2003","unstructured":"Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, Rane A: Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics. 2003, 13 (12): 715-720. 10.1097\/00008571-200312000-00002.","journal-title":"Pharmacogenetics"},{"issue":"6","key":"538_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","volume":"45","author":"JO Miners","year":"1998","unstructured":"Miners JO, Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998, 45 (6): 525-538. 10.1046\/j.1365-2125.1998.00721.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"538_CR9","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S0169-409X(02)00076-5","volume":"54","author":"HG Xie","year":"2002","unstructured":"Xie HG, Prasad HC, Kim RB, Stein CM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002, 54 (10): 1257-1270. 10.1016\/S0169-409X(02)00076-5.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"538_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/sj.bjp.0705623","volume":"141","author":"C Martinez","year":"2004","unstructured":"Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, Diaz-Rubio M, Agundez JA: Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004, 141 (2): 205-208. 10.1038\/sj.bjp.0705623.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"538_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/01.GIM.0000153664.65759.CF","volume":"7","author":"S Sanderson","year":"2005","unstructured":"Sanderson S, Emery J, Higgins J: CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005, 7 (2): 97-104. 10.1002\/ajmg.a.30391.","journal-title":"Genet Med"},{"issue":"4","key":"538_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00008571-200106000-00002","volume":"11","author":"J van der Weide","year":"2001","unstructured":"Weide van der J, Steijns LS, van Weelden MJ, de Haan K: The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics. 2001, 11 (4): 287-291. 10.1097\/00008571-200106000-00002.","journal-title":"Pharmacogenetics"},{"key":"538_CR13","unstructured":"Whatman FTA Protocol. [ http:\/\/www.kirkhousetrust.org\/Docs\/FTAProtocolBD08.pdf ]"},{"issue":"11","key":"538_CR14","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0006-2952(02)01354-0","volume":"64","author":"N Bahadur","year":"2002","unstructured":"Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, et al: CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol. 2002, 64 (11): 1579-1589. 10.1016\/S0006-2952(02)01354-0.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"538_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1046\/j.1365-2125.2003.01937.x","volume":"56","author":"AC Allabi","year":"2003","unstructured":"Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y: Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol. 2003, 56 (6): 653-657. 10.1046\/j.1365-2125.2003.01937.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"538_CR16","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/clinchem\/47.4.772","volume":"47","author":"M Hersberger","year":"2001","unstructured":"Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E: Two single-tube tetra-primer assays to detect the CYP2C19*2 and *3 alleles of S-mephenytoin hydroxylase. Clin Chem. 2001, 47 (4): 772-774.","journal-title":"Clin Chem"},{"issue":"12","key":"538_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/j.1365-3156.2005.01525.x","volume":"10","author":"SBU Rower","year":"2005","unstructured":"Rower SBU, Weise A, Lambertz U, Frost T, Otchwemah RN, Pfutzner A, Mockkenhaupt F: High prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Tropical Medicine and International Health. 2005, 10 (12): 1271-1273.","journal-title":"Tropical Medicine and International Health"},{"issue":"10","key":"538_CR18","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.amjhyper.2005.04.019","volume":"18","author":"AW Dreisbach","year":"2005","unstructured":"Dreisbach AW, Japa S, Sigel A, Parenti MB, Hess AE, Srinouanprachanh SL, Rettie AE, Kim H, Farin FM, Hamm LL, et al: The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens. 2005, 18 (10): 1276-1281. 10.1016\/j.amjhyper.2005.04.019.","journal-title":"Am J Hypertens"},{"issue":"2","key":"538_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/sj.clpt.6100122","volume":"82","author":"S Parikh","year":"2007","unstructured":"Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL: Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007, 82 (2): 197-203. 10.1038\/sj.clpt.6100122.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"538_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00228-004-0871-8","volume":"61","author":"I Cavaco","year":"2005","unstructured":"Cavaco I, Stromberg-Norklit J, Kaneko A, Msellem MI, Dahoma M, Ribeiro VL, Bjorkman A, Gil JP: CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol. 2005, 61 (1): 15-18. 10.1007\/s00228-004-0871-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"538_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0006-291X(02)02592-5","volume":"299","author":"U Yasar","year":"2002","unstructured":"Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, Rane A: Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun. 2002, 299 (1): 25-28. 10.1016\/S0006-291X(02)02592-5.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3-4","key":"538_CR22","first-page":"141","volume":"50","author":"A Weise","year":"2004","unstructured":"Weise A, Grundler S, Zaumsegel D, Klotzek M, Grondahl B, Forst T, Pfutzner A: Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clin Lab. 2004, 50 (3-4): 141-148.","journal-title":"Clin Lab"},{"issue":"12","key":"538_CR23","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/j.1365-3156.2005.01525.x","volume":"10","author":"S Rower","year":"2005","unstructured":"Rower S, Bienzle U, Weise A, Lambertz U, Forst T, Otchwemah RN, Pfutzner A, Mockenhaupt FP: Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health. 2005, 10 (12): 1271-1273.","journal-title":"Trop Med Int Health"},{"issue":"4","key":"538_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1046\/j.0306-5251.2001.01460.x","volume":"52","author":"MG Scordo","year":"2001","unstructured":"Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol. 2001, 52 (4): 447-450. 10.1046\/j.0306-5251.2001.01460.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"538_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00008571-199706000-00005","volume":"7","author":"CL Crespi","year":"1997","unstructured":"Crespi CL, Miller VP: The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics. 1997, 7 (3): 203-210. 10.1097\/00008571-199706000-00005.","journal-title":"Pharmacogenetics"},{"issue":"2","key":"538_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/00008571-200003000-00001","volume":"10","author":"K Takanashi","year":"2000","unstructured":"Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K: CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics. 2000, 10 (2): 95-104. 10.1097\/00008571-200003000-00001.","journal-title":"Pharmacogenetics"},{"issue":"Suppl 2","key":"538_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.1365-2362.33.s2.6.x","volume":"33","author":"UI Schwarz","year":"2003","unstructured":"Schwarz UI: Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest. 2003, 33 (Suppl 2): 23-30. 10.1046\/j.1365-2362.33.s2.6.x.","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"538_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00008571-200204000-00010","volume":"12","author":"CR Lee","year":"2002","unstructured":"Lee CR, Goldstein JA, Pieper JA: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002, 12 (3): 251-263. 10.1097\/00008571-200204000-00010.","journal-title":"Pharmacogenetics"},{"issue":"7","key":"538_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1532-5415.1996.tb03729.x","volume":"44","author":"RI Shorr","year":"1996","unstructured":"Shorr RI, Ray WA, Daugherty JR, Griffin MR: Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996, 44 (7): 751-755.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"538_CR30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0002-9343(99)00267-3","volume":"107","author":"RH White","year":"1999","unstructured":"White RH, Beyth RJ, Zhou H, Romano PS: Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 1999, 107 (5): 414-424. 10.1016\/S0002-9343(99)00267-3.","journal-title":"Am J Med"},{"issue":"4","key":"538_CR31","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","volume":"46","author":"SM De Morais","year":"1994","unstructured":"De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994, 46 (4): 594-598.","journal-title":"Mol Pharmacol"},{"issue":"22","key":"538_CR32","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","volume":"269","author":"SM de Morais","year":"1994","unstructured":"de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994, 269 (22): 15419-15422.","journal-title":"J Biol Chem"},{"issue":"1","key":"538_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/00008571-199702000-00008","volume":"7","author":"JA Goldstein","year":"1997","unstructured":"Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997, 7 (1): 59-64. 10.1097\/00008571-199702000-00008.","journal-title":"Pharmacogenetics"},{"issue":"1","key":"538_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s002280100282","volume":"57","author":"C Dandara","year":"2001","unstructured":"Dandara C, Masimirembwa CM, Magimba A, Sayi J, Kaaya S, Sommers DK, Snyman JR, Hasler JA: Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol. 2001, 57 (1): 11-17. 10.1007\/s002280100282.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"538_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00228-003-0606-2","volume":"59","author":"EA Gaikovitch","year":"2003","unstructured":"Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, Gerloff T, Chernov JN, Roots I: Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol. 2003, 59 (4): 303-312. 10.1007\/s00228-003-0606-2.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"538_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/00008571-199412000-00001","volume":"4","author":"JA Goldstein","year":"1994","unstructured":"Goldstein JA, de Morais SM: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994, 4 (6): 285-299. 10.1097\/00008571-199412000-00001.","journal-title":"Pharmacogenetics"},{"issue":"4","key":"538_CR37","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2133\/dmpk.20.300","volume":"20","author":"H Fukushima-Uesaka","year":"2005","unstructured":"Fukushima-Uesaka H, Saito Y, Maekawa K, Ozawa S, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, et al: Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab Pharmacokinet. 2005, 20 (4): 300-307. 10.2133\/dmpk.20.300.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"538_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00008571-200302000-00005","volume":"13","author":"B Chowbay","year":"2003","unstructured":"Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics. 2003, 13 (2): 89-95. 10.1097\/00008571-200302000-00005.","journal-title":"Pharmacogenetics"},{"issue":"5","key":"538_CR39","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00228-004-0766-8","volume":"60","author":"K Grasmader","year":"2004","unstructured":"Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML: Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004, 60 (5): 329-336. 10.1007\/s00228-004-0766-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7-8","key":"538_CR40","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1177\/106002809302700702","volume":"27","author":"TR Einarson","year":"1993","unstructured":"Einarson TR: Drug-related hospital admissions. Ann Pharmacother. 1993, 27 (7-8): 832-840.","journal-title":"Ann Pharmacother"},{"issue":"15","key":"538_CR41","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","volume":"279","author":"J Lazarou","year":"1998","unstructured":"Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998, 279 (15): 1200-1205. 10.1001\/jama.279.15.1200.","journal-title":"Jama"},{"issue":"3","key":"538_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/BF03256456","volume":"10","author":"TM Bosch","year":"2006","unstructured":"Bosch TM, Doodeman VD, Smits PH, Meijerman I, Schellens JH, Beijnen JH: Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Mol Diagn Ther. 2006, 10 (3): 175-185.","journal-title":"Mol Diagn Ther"},{"issue":"3","key":"538_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1046\/j.1365-2125.2003.01883.x","volume":"56","author":"C Adithan","year":"2003","unstructured":"Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, Krishnamoorthy R: Allele and genotype frequency of CYP2C19 in a Tamilian population. Br J Clin Pharmacol. 2003, 56 (3): 331-333. 10.1046\/j.1365-2125.2003.01883.x.","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-10-124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2350-10-124\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-10-124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:52:10Z","timestamp":1739461930000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedgenet.biomedcentral.com\/articles\/10.1186\/1471-2350-10-124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["538"],"URL":"https:\/\/doi.org\/10.1186\/1471-2350-10-124","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]},"article-number":"124"}}